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The effect of erythromycin on gastrointestinal motility 
in subtotal gastrectomized patients
A-Lan Lee, Choong-Bai Kim
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Purpose: Our objective was to determine the effect of erythromycin (EM) in improving gastrointestinal motility in subtotal 
gastrectomized patients. We used radio-opaque Kolomarks as an objective method. We conducted a prospective, controlled 
clinical trial study of 24 patients. Methods: All patients underwent subtotal gastrectomy with 3 capsules containing 
Kolomarks (20 markers per 1 capsule) in the remnant stomach before anastomosis. From the day of the operation to the 2nd 
postoperative day, patients in the EM group began receiving 200 mg of EM intravenously for 30 minutes continuously. We 
counted the number of Kolomarks in the stomach, passed by stomach, in rectum, and in stool with serial simple abdominal 
X-ray films on the first postoperative day up to the 7th postoperative day. Results: The study population included 14 patients 
in the control group and 10 patients in the EM group. The two study groups were compared in terms of their characteristics 
including age, gender, past medical history, cancer stage, and operation type. No significant differences were found for the 
demographics between the two groups. We only found a significant difference for the number of Kolomarks passed by the 
stomach on the 3rd postoperative day (P = 0.026). Conclusion: Our results demonstrated that 200 mg of EM intravenous in-
fusion during the postoperative period induced rapid gastric emptying, although it did not improve gastrointestinal motility 
for the entire gastrointestinal tract in subtotal gastrectomized patients.
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INTRODUCTION
 Postoperative ileus is an inevitable event after major 
abdominal surgery. It is caused by the cessation of the mi-
grating motor complex (MMC), by hyperactivity of the 
sympathetic nervous system, by local inflammation sec-
ondary to surgery, and by the inhibitory effect of endoge-
nous or exogenous opioids on gastrointestinal motility. 
Clinically, it is characterized by bowel distention, lack of 
bowel sounds, accumulation of gastrointestinal gas and 
fluid, and delayed passage of flatus and stool. Postoper-
ative ileus can lead to cramp abdominal pain, nausea, 
vomiting, and potential complications including aspira-
tion and acute gastric distention. When it is prolonged, 
postoperative ileus can lead to increased morbidity due to 
nutritional imbalance, length of hospital stay, and health-
care cost. For these reasons, in particular, several pharma-
cological managements have been proposed [1].
Erythromycin (EM) is a well-known prokinetic agent. In 
patients with diabetic gastroparesis, EM, which stimulates 
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the gastric antral and duodenal motilin receptor, sig-
nificantly improves delayed gastric emptying of both sol-
ids and liquids [2]. It has also been shown to have potential 
benefits in patients with postvagotomy gastroparesis [3]. 
Although studies on the effects of EM in postoperative 
ileus are progressing these days, there have been only a 
few well designed clinical trials that have examined the 
use of EM in the postoperative setting [4-9].
The aim of this study was to determine the effect of EM 
for the improvement of gastrointestinal motility in sub-
total gastrectomized patients. We used radio-opaque 
Kolomarks as the objective method. Therefore, we hy-
pothesized that Kolomarks would pass through the gas-
trointestinal tract more rapidly in the EM group than in the 
control group.
METHODS
Data collection
The study was designed and implemented as a pro-
spective, controlled clinical trial. From March 2007 to 
February 2008, all patients who were scheduled for sub-
total gastrectomy due to gastric cancer at our institution 
were included in the study. The institutional review board 
approved this study, and each participant provided in-
formed, written consent.
The patients were selected to one of two groups, either 
the control or EM group. Starting from the day of the oper-
ation to the 2nd postoperative day, patients in the EM 
group received intravenously 200 mg of EM infusion for 
30 minutes in 100 mL of normal saline at 7:00 PM. In the 
control group, the patients were treated with conventional 
management without prokinetic agents. All patients dur-
ing the observation period had their perioperative medi-
cations related to gastrointestinal motility stopped except 
for EM in the EM group.
Surgical methods
All patients had stomach cancer. We classified the can-
cer staging using the American Joint Committee on 
Cancer, 8th edition. Subtotal gastrectomy with gastro-
duodenostomy (Billroth I) or gastrojejunostomy (Billroth 
II) was done by one surgeon at our institution. In addition, 
all patients had a truncal vagotomy done. At the last stage 
of the operation, we left 3 capsules (20 markers of Kolo-
marks per 1 capsule), for a total of 60 Kolomarks in the 
remnant stomach. During the operation, there were no 
complications and problems. We did not insert a nasogas-
tric tube into patients during the postoperative period. 
Preoperative bowel preparation used one bottle of oral so-
dium biphosphate and one-half polyethylene glycol. 
Postoperative pain medications included patient-con-
trolled analgesia with opioids and local analgesia ad-
ministered by the anesthesiologist. 
Data analysis 
All patients in both groups had abdominal X-ray films 
taken on the 1st, 3rd, 5th, and 7th postoperative day. We 
counted the number of Kolomarks on each day. In addi-
tion, all patients had their passage of flatus checked daily 
by patient interview. We allowed all patients to have a 
meal after passage of flatus starting from sips of water to a 
soft diet in an incrementally manner each day. The length 
of the hospital stay was from the day of the operation to the 
discharge day since the patients’ hospital stay for the pre-
operative evaluation varied. Glucose levels were meas-
ured on the 1st, 3rd, and 7th postoperative day in order to 
identify the correlation to bowel motility. We decided to 
discharge the patients, when the patients had a tolerable 
soft diet.
No adverse side effects potentially caused by EM were 
found in patients, which included nausea, emesis, ab-
dominal pain, allergic reaction, and arrhythmia. 
Statistical analysis
Comparisons between patients with and without EM 
with regards to demographics (age, gender), clinical pa-
rameters (past medical history, cancer stage, operation 
type, patients-controlled analgesia [PCA] categories), and 
outcomes (passage of flatus, lengths of hospital stay, glu-
cose levels, number of Kolomarks) were carried out using 
chi-square test (nominal data), unpaired independent 
t-tests, and Mann-Whitney test. The Mann-Whitney test 
was used since the continuous parameters did not follow 
a normal distribution. Statistical analysis was done with 
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Characteristic Control group (n = 14)
EM group 
(n = 10) P-value
Age (yr) 54.4 ± 11.9
(38-78)
55.6 ± 11.8 
(37-71)
0.814
Sex
  Male
  Female
8 (57.1)
6 (42.9)
2 (20.0)
8 (80.0)
0.069
Past medical history
  Hypertension 4 (28.6) 1 (10.0)
0.269
Stage
  I
  II
  III
9 (64.3)
5 (35.7)
       0 (0)
7 (70.0)
1 (10.0)
2 (20.0)
0.112
Operation type
  Billroth I
  Billroth II
8 (57.1)
6 (42.9)
6 (60.0)
4 (40.0)
0.889
PCA categories
  Epidural (thoracic) 
  Epidural (lumbar)
  Intravenous
     10 (71.4)
2 (14.3)
2 (14.3)
9 (90.0)
1 (10.0)
     0 (0)
0.413
Values are presented as mean ± SD (range) or number (%).
EM, erythromycin; PCA, patients-controlled analgesia.
Table 1. Demographics of the patients
Fig. 1. Abdominal X-ray film in erythromycin group on 1st 
postoperative day. There are 57 Kolomarks in stomach.
SPSS ver. 18.0 (IBM, New York, NY, USA). A P-value ＜ 
0.05 was considered significant for all tests done.
RESULTS
Demographics of the patients
Twenty-eight patients were enrolled in the study. Three 
patients with diabetes were excluded because we identi-
fied that the stimulation of antral motility by EM was atte-
nuated by hyperglycemia [10]. In addition, another pa-
tient with esophageal cancer was ruled out due to a de-
layed hospital stay. The data from the 24 patients were 
used for the calculations in this study. The study pop-
ulation included 14 patients in the control group and 10 
patients in the EM group. Comparisons between the two 
groups were done for age, gender, past medical history, 
cancer stage, operation type, and PCA categories. The 
average age for the control group and EM group was 54.4 
± 11.9 and 55.6 ± 11.8, respectively. Each group did not 
have any significant differences in operation type and can-
cer stage (Billroth I, 8 [57.1%] in control group vs. 6 [60%] 
in EM group; Billroth II, 6 [42.9%] in control group vs. 4 
[40%] in EM group; stage I, II, III, 9 [64.3%], 5 [35.7%], 0 [0] 
in control group vs. 7 [70%], 1 [10%], 2 [20%] in EM group). 
However, no significant differences were found for the 
demographics between the two groups (Table 1). 
Clinical outcomes
The mean values for the glucose levels on the 1st, 3rd, 
and 7th postoperative day were higher in the EM group 
than in the control group, although there were no sig-
nificant differences in each group. The mean values in the 
EM group for the passage of flatus and length of hospital 
stay were lower than in the control group. However, no 
significant differences were founded in each group (80.6 ± 
23.8 in the control group vs. 78.8 ± 7.6 in the EM group; P = 
0.744). Abdominal X-ray films were used to count the 
number of Kolomarks for each postoperative day (Figs. 
1-4). On the 1st postoperative day, the mean value of the 
number of Kolomarks in the stomach was found to be 
higher in EM group than in the control group (54.8 ± 8.0 in 
the control group vs. 55.5 ± 4.9 in the EM group). The mean 
value of the number of Kolomarks passed by stomach on 
the 3rd postoperative day in the EM group was higher 
than in the control group (30.8 ± 25.6  in the control group 
vs. 49.9 ± 17.7 in the EM group). The mean values of the 
number of Kolomarks in the rectum on the 3rd post-
operative day and in the stool on 5th and 7th postoperative 
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Fig. 2. Abdominal X-ray film in erythromycin group on 3rd 
postoperative day. All Kolomarks were passed by stomach.
Fig. 4. Abdominal X-ray film in erythromycin group on 7th 
postoperative day. Twenty Kolomarks are remained in gastro-
intestinal tract.
Fig. 3. Abdominal X-ray film in erythromycin group on 5th 
postoperative day. Picture shows that most Kolomarks in the 
gastrointestinal tract remained except 4.
day, also, were higher in the EM group than in the control 
group (0.4 ± 0.7 in the control group vs. 1.2 ± 1.6 in the EM 
group, 5.2 ± 12.4 in the control group vs. 10.5 ± 17.7 in the 
EM group, 19.9 ± 22.6 in the control group vs. 23.6 ± 25.1 in 
the EM group, respectively). However, we only found a 
significant difference for the number of Kolomarks passed 
by the stomach on the 3rd postoperative day (P = 0.026) 
(Table 2).
DISCUSSION
Motilin is a 22-amino acid that is secreted by the enter-
ochromaffin cells of the duodenum and proximal small 
intestine. This hormone binds to high affinity motilin re-
ceptors that have been found in the stomach, the duode-
num, and the colon [11]. Motilin receptor stimulation ini-
tiates the interdigestive (phase III) MMC. Return of an ef-
fective MMC is one of the important components for the 
resolution of postoperative ileus. 
EM, discovered in 1952, was the first macrolide to be in-
troduced into clinical practice [12]. It has been known for 
over 25 years that it acts as a motilin receptor agonist in the 
gut and gallbladder [13]. The intravenous form is the most 
potent stimulant of solid and liquid gastric emptying 
[14,15]. EM binds to motilin receptors and hence, increases 
the amplitude of antral peristalsis, triggers premature 
MMC phase III activity, and stimulates gastric emptying 
[16]. 
Different doses of EM may have different effects [2]. 
Forty milligrams of EM elicit premature phase 3 com-
plexes that start in the stomach and migrate to the small in-
testine, while doses of 200 and 350 mg of EM elicit a burst 
of antral phase-3-like contractions that do not migrate to 
the small intestine, but are followed by a prolonged period 
The effect of erythromycin in gastrectomized patients
thesurgery.or.kr 153
Outcome Control group (n = 14) EM group (n = 10) P-value
Passage of flatus (hr)
Lengths of hospital stay (day) 
  80.6 ± 23.8 (45-120)
  11.4 ± 2.2 (9-15)
  78.8 ± 7.6 (72-90)
  10.9 ± 2.8 (9-18)
0.744
0.418
Glucose levels
  POD 1
  POD 3
  POD 7
119.1 ± 22.9 (92-163)
109.9 ± 18.8 (85-148)
108.4 ± 21.5 (82-164)
132.5 ± 33.0 (90-210)
116.8 ± 22.5 (98-165)
118.4 ± 17.8 (100-158)
0.250
0.429
0.079
No. of Kolomarks
  POD 1 (in stomach)
  POD 3 (passed by stomach)
  POD 3 (in rectum)
  POD 5 (in stool)
  POD 7 (in stool)
  54.8 ± 8.0 (33-60)
  30.8 ± 25.6 (0-60)
    0.4 ± 0.7 (0-2)
    5.2 ± 12.4 (0-47)
  19.9 ± 22.6 (0-57)
  55.5 ± 4.9 (46-60)
  49.9 ± 17.7 (10-60)
    1.2 ± 1.6 (0-4)
  10.5 ± 17.7 (0-58)
  23.6 ± 25.1 (0-60)
0.590
0.026
0.133
0.081
0.953
Values are presented as mean ± SD (range).
EM, erythromycin; POD, postoperative day.
Table 2. Clinical outcomes
of antral contractile activity. Motilin receptors are most 
dense in the stomach and decrease in density as they prog-
ress distally through the GI tract. Evidence suggests that 
motilin receptors are present in the colon but to a consid-
erably lesser degree than in the remainder of the GI tract 
[11,17-19]. Consequently, the effect of EM on colonic mo-
tility and on the treatment of lower GI abnormalities has 
been inconsistent [20].
Interestingly, EM has also been shown to accelerate 
emptying in post-vagotomy and antrectomy patients [21]. 
This may be due to its stimulatory effects on the fundus. 
Vagus nerve activity appears to be more important in the 
stomach, where it promotes receptive relaxation of the 
fundus and contraction of the antrum, facilitating gastric 
emptying [22]. After vagotomy, emptying of liquids may 
be normal or accelerated, but emptying of solids is 
impaired. This can occur after peptic ulcer surgery but is 
more likely after gastric resection for malignancy or after 
inadvertent vagal nerve injury during antireflux surgery. 
In patients who underwent antrectomy and vagotomy, 
EM was shown to accelerate gastric emptying by roughly 
40% as measured by solid-phase gastric emptying scintig-
raphy [15,21]. In a randomized controlled trial in 118 pa-
tients who underwent pancreaticoduodenectomy, intra-
venous EM reduced gastroparesis by 37% (measured by 
solid-phase gastric emptying study) and also reduced the 
need for nasogastric tube reinsertion [6]. 
In our study, we expected that the migration velocity of 
the Kolomarks passed by the stomach would accelerate in 
the EM group, although the patients had received a trun-
cal vagotomy. As a result, we found that Kolomarks in the 
EM group were passed by the stomach more rapidly than 
in the control group on the 3rd postoperative day. There 
have been several studies on EM use postoperatively 
[4-6,8,9,23]. However, the studies did not prove exactly the 
effects of EM in the gastrointestinal tract postoperatively. 
Most of those studies used clinical parameters in order to 
obtain endpoints. Our study was more accurate than the 
other studies since the results of our study were calculated 
by an objective method (Kolomarks). However, our study 
also had limitations. Although we were able to distinguish 
between stomach gas and transverse colon gas, Kolo-
marks located in the transverse colon were confusing. In 
addition, there was some overlap when counting Kolo-
marks.
The pathogenesis of postoperative ileus is multi-
factorial. Therefore, we should approach the treatment of 
postoperative ileus diversely. Various medications have 
been used in an attempt to shorten the length of post-
operative ileus after abdominal surgery, including antie-
metics and prokinetics. Metoclopramide is an antiemetic 
and prokinetic agent that acts as a dopamine D2 receptor 
antagonist and mixed serotonin 5-HT3 antagonist/5-HT4 
agonist. Metoclopramide also stimulates gastric empty-
ing, as shown in controlled trials in patients in intensive 
care units [24]. The drug should not be used in patients 
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with parkinsonism, due to its antidopamine properties. 
Neostigmine (Prostigmin) is a reversible acetylcholines-
terase inhibitor that enhances the activity of neuro-
transmitter acetylcholine at muscarinic receptors. It is the 
first-line treatment for colonic ileus [25]. Alvimopan is an 
orally administered, peripherally acting antagonist for the 
μ-opioid receptor, which was developed as a potential 
treatment for postoperative ileus and opioid bowel dys-
function. In an early trial with 78 surgical patients, alvimo-
pan demonstrated proof of principle that the μ-opioid re-
ceptor antagonistic activity shortened both postoperative 
ileus and hospital stay without compromising opioid- 
mediated analgesia [26].
In addition to previous mentioned pharmacological 
treatments, recently, methods that decrease local inflam-
mation and opioids have been in the spotlight. Laparosco-
pic surgery has several advantages over open surgery. 
With smaller incisions, it is less traumatic to the body. The 
systemic inflammatory response appears to be less vigo-
rous after laparoscopic surgery than after open surgery, as 
measured by circulating levels of interleukin (IL) 1, IL 6, 
and C-reactive protein [27]. Thoracic epidural analgesia 
has been shown to hasten the return of bowel function by 
1 to 2 days and to reduce the need for opiates compared 
with systemic opioids alone [28].
We have demonstrated that intravenously infusion of 
200 mg of EM in gastrorectomized patients induced rapid 
gastric emptying. However, the effect of EM is not enough 
for the entire gastrointestinal tract in postoperative pa-
tients. We expected that the recovery of the patients would 
be accelerated by proper nutritional support, and con-
sequently, morbidity and length of hospital stay would de-
crease since the patients in the EM group after abdominal 
surgery had improved gastrointestinal motility. Although 
we identified the effect of EM in the stomach, we did not 
obtain satisfactory results for the passage of flatus and 
length of hospital stay and for the effect of EM in the small 
intestine and colon. We think that the results were influ-
enced by doses and periods of application for EM as well 
as insufficient case number (total 24 patients), selection 
bias, and difficulties for counting Kolomarks. Therefore, 
even if we could use EM carefully for improvement of gas-
tric emptying in postoperative patients, further studies 
with more randomized data number about doses and per-
missible periods of application for EM are needed to found 
the effect of EM in the entire gastrointestinal tract. 
Moreover, we should find a solution for postoperative 
ileus through studies on the exact impact of EM on the gas-
trointestinal tract as well as combination therapies. 
In conclusion, our results have demonstrated that 200 
mg of EM intravenously infusion during the post-
operative period induced rapid gastric emptying, al-
though it did not improve gastrointestinal motility for the 
entire gastrointestinal tract in subtotal gastrectomized 
patients.
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